Contact Us
Drug Search Results
More Filters [+]

EGEN-001

Alternative Names: EGEN-001, egen-001-301, egen001301, egen 001 301, EGEN001, EGEN-001 (phIL-12-005/PPC), phIL-12-005
Latest Update: 2019-03-12
Latest Update Note: Clinical Trial Update

Product Description

An IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer (Sourced from: https://pubmed.ncbi.nlm.nih.gov/24708919/)

Mechanisms of Action: IL12 Analogue

Novel Mechanism: Yes

Modality: Gene Therapy

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: EGEN
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for EGEN-001

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Peritoneal Cancer|Colorectal Cancer

Phase 1: Mucinous Cystadenocarcinoma|Endometrioid Carcinoma|Clear Cell Adenocarcinoma|Serous Cystadenocarcinoma|Ovarian Cancer|Peritoneal Cancer|Mucinous Adenocarcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
GOG-9928

P1

Completed

Ovarian Cancer|Clear Cell Adenocarcinoma|Endometrioid Carcinoma|Mucinous Adenocarcinoma|Mucinous Cystadenocarcinoma|Serous Cystadenocarcinoma

2014-12-30

EGEN-001-301

P2

Terminated

Colorectal Cancer|Peritoneal Cancer

2014-07-01

EGEN-001-201

P1

Completed

Ovarian Cancer|Peritoneal Cancer

2009-11-01

EGEN-001-101

P1

Terminated

Ovarian Cancer|Peritoneal Cancer

2006-10-01

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions